Ricefidase

Phase I clinical trials of KJ103, a novel IgG degrading enzyme, demonstrate its safety, tolerability, and efficacy in reducing IgG levels in healthy volunteers. Conducted in China and New Zealand, the studies highlight KJ103's potential in clinical applications, including gene therapy and organ transplantation, by efficiently cleaving IgG and maintaining low serum levels without severe adverse effects.

KisoJi Biotechnology has raised $41 million to advance its lead asset, KJ-103, a novel antibody targeting TROP2, into clinical trials for solid tumors.

Cancer Research UK and KisoJi Biotechnology have partnered to initiate a Phase 1/2a clinical trial for KJ-103, a novel naked anti-TROP2 antibody.

Cancer Research UK and KisoJi Biotechnology have partnered to advance KJ-103, a novel anti-TROP2 antibody, into Phase 1/2a clinical trials for TROP2-expressing solid tumors.

Cancer Research UK and KisoJi Biotechnology will collaborate to advance KJ-103, a novel naked anti-TROP2 antibody, into a Phase 1/2a clinical trial.